Health Care · Services-Commercial Physical & Biological Research

ABSI Absci Corp SEC Filings & Insider Trading Activity 2026

company
CIK 167268879 filings
Russell 2000

ABSI at a glance

Absci Corp (ABSI, SEC CIK 1672688) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and Form 4 insider filings as recently as October 30, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Absci Corp (ABSI) reported revenue of $2.8 million (down 38.2% from FY2024) and a net loss of $115.2 million. Diluted EPS was -$0.84.
  • As of September 30, 2026, 30 institutional investment managers tracked by SignalX reported holding Absci Corp (ABSI) shares worth $791.6 million in 13F-HR filings.
  • The most recent insider open-market purchase reported on Form 4 was by Szela Mary T on June 30, 2026 of 12,900 shares at $11.54 per share.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.8M
−38.2% vs prior year
Insiders · 90 days
0 buys · 0 sells
No open-market trades
13F holders
30 funds
$791.6M · +1 vs prior quarter
Latest 8-K
Nov 12, 2026
Item 2.02 · Item 8.01

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • Newly added BIOSECURE Act risk: WuXi AppTec’s June 2026 designation was preliminarily enjoined in August 2026
  • Regulatory risk: CMS finalized GLOBE Model for 2027, potentially reducing partner revenue, milestones and royalties
  • Clinical risk: ABS-201 Phase 1/2a trial continues dosing MAD cohorts in Australia
  • Financial risk: $173.7 million cash, equivalents and marketable securities expected to fund at least 12 months
  • Operating risk: No partner has licensed related intellectual property for clinical or commercial use as of November 12, 2026

Management Discussion & Analysis

  • Revenue $0.3M, down 20% YoY from $0.4M, reflecting milestone timing and program mix
  • Operating loss $35.0M vs $30.2M YoY, with R&D expense $23.6M, up 22%
  • Lead program ABS-201: positive interim safety data, half-life at least 65 days
  • Cash, equivalents and marketable securities $173.7M; operating cash used $83.3M through nine months
  • June offering generated $93.6M; management expects liquidity sufficient for at least 12 months

AI summary of the ABSI 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 12, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Third-quarter fiscal 2026 results announced for period ended September 30, 2026
  • Full financial results and management commentary available in Exhibit 99.1

Item 8.01: Other Events

  • Absci released an investor presentation on November 12, 2026 covering internal pipeline program updates
  • Pipeline disclosures may affect investor views on development priorities, clinical progress and future catalysts

Item EX-99.2: Item EX-99.2

  • Corporate presentation highlights ABS-201’s Ph1/2a PHL program, with interim proof-of-concept readout expected December 2026
  • Interim SAD data showed favorable blinded safety and tolerability, with half-life of at least 65 days

Item EX-99.1: Item EX-99.1

  • ABS-201 HEADLINE trial on track, with 13-week pattern hair-loss proof-of-concept data expected December 2026 and full 26-week data early 2027
  • Planned Phase 2 STORYLINE endometriosis trial targets approximately 150 patients across approximately 10 countries, with initiation anticipated mid-2027
Filed Aug 11, 2026Full analysis →

Item 8.01: Other Events

  • Absci released an August 11, 2026 investor presentation with internal pipeline program updates
  • Presentation provides investors current visibility into drug-development priorities and pipeline progress

Item EX-99.1: Item EX-99.1

  • Positive interim Phase 1 ABS-201 data: favorable safety profile and estimated half-life of at least 65 days
  • Pattern hair-loss interim proof-of-concept data expected second half 2026, with full readout targeted for early 2027

Item 2.02: Results of Operations and Financial Condition

  • Q2 2026 results for quarter ended June 30, 2026 announced on August 11, 2026
  • Press release containing financial results furnished as Exhibit 99.1, the key source for investor review
Filed Jun 24, 2026Full analysis →

Item 8.01: Other Events

  • Interim Phase 1 data released for ABS-201 in the HEADLINE™ trial
  • Clinical update creates a potential valuation catalyst for Absci’s drug-development pipeline

Item EX-99.1: Item EX-99.1

  • Positive Phase 1 safety signal: 32 participants across 150–1800 mg SAD cohorts, with no serious adverse events
  • ABS-201 half-life estimated at least 65 days, supporting potential two- or three-dose administration over six months

AI summaries of ABSI 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for ABSI

Don't miss the next ABSI filing

  • Alerts as it files. A push when ABSI files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut ABSI, by share count.
  • Ask anything. An AI agent that reads every ABSI filing and answers with sources.

ABSI alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
McClain SeanFOct 29, 2026$12.10
McClain SeanFOct 12, 2026$10.16
Bedrick ToddFOct 12, 2026$10.16
Jonasson ZachariahFOct 12, 2026$10.16
Jonasson ZachariahFAug 31, 2026$8.71
Somaratne Ransi MudalinayakeAAug 3, 2026-
Szela Mary TBuyJun 30, 2026$11.54
McClain SeanFJun 24, 2026$10.07

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$4.5M$2.8M
Operating Income--$108.9M-$120.3M
Net Income-$110.6M-$103.1M-$115.2M
Op. Margin--2401.6%-4297.0%
Net Margin--2274.1%-4113.7%
Balance Sheet
Total Assets$217.3M$213.6M$216.3M
Equity-$179.1M$189.4M
ROE--57.6%-60.8%
Per Share
EPS$-1.20$-0.94$-0.84
Cash Flow
Operating CF--$72.4M-$92.9M
CapEx$860K$404K$1.1M

Source: XBRL data in Absci Corp (ABSI)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate ABSI share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
ABSI shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202630$791.6M
Q2 202629$1.15B
Q1 202630$241.4M
Q4 202525$281.0M
Q3 202526$190.8M
Q2 202525$143.4M
Q1 202523$117.1M
Q4 202419$93.5M
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 207 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

ABSI filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
10-QNov 12, 2026Analysis
8-KNov 12, 2026Analysis-
4Oct 30, 2026--
4Oct 14, 2026--
4Oct 14, 2026--
4Oct 14, 2026--
4Sep 1, 2026--
10-QAug 11, 2026Analysis
8-KAug 11, 2026Analysis-
4Aug 7, 2026--
4Jul 6, 2026--
4Jun 26, 2026--
8-KJun 24, 2026Analysis-
8-KJun 24, 2026Analysis-
4Jun 15, 2026--
4Jun 11, 2026--
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
4Jun 8, 2026-
8-KJun 5, 2026Analysis
4Jun 1, 2026-
4May 13, 2026-
10-QMay 7, 2026Analysis

Related Health Care companies

All Health Care →

ABSI SEC filings: frequently asked questions

Which institutions hold ABSI stock?

As of September 30, 2026, the largest Absci Corp (ABSI) holders among the 13F filers tracked by SignalX were BlackRock ($156.2 million), ARK Investment Management ($128.5 million), State Street Corp ($91.1 million), Vanguard Capital Management LLC ($75.8 million), Advanced Micro Devices ($61.5 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was ABSI's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Absci Corp (ABSI) reported revenue of $2.8 million (down 38.2% from FY2024) and a net loss of $115.2 million. Diluted EPS was -$0.84. The figures come from the XBRL data in the 10-K.

What did ABSI report in its latest 8-K?

Absci Corp (ABSI) filed an 8-K on November 12, 2026 reporting Item 2.02 (Results of Operations and Financial Condition) and Item 8.01 (Other Events). Third-quarter fiscal 2026 results announced for period ended September 30, 2026.

What are the latest ABSI SEC filings?

Absci Corp (ABSI) filed its latest 10-K annual report on March 24, 2026, a 10-Q quarterly report on November 12, 2026, an 8-K current report on November 12, 2026 and a Form 4 insider filing on October 30, 2026.

What is ABSI's SEC CIK number?

Absci Corp (ABSI)'s SEC Central Index Key (CIK) is 1672688. EDGAR lists every ABSI filing under that number.

Ask anything about ABSI

The research agent reads ABSI's filings, financials, insider trades and 13F holders, then answers with sources.